Introduction: Hepatitis E virus (HEV) is an emerging cause of autochthonous-acute-hepatitis and acute-on-chronic-liver-failure in western countries. Treatment is not routinely used, despite ribavirin has a good antiviral effect. In vitro sofosbuvir inhibits HEV replication, but clinical data are lacking. Case report: We report a case of acute-on-chronic-liver-failure due to HEV treated with sofosbuvir and ribavirin. The treatment was capable of rapidly inducing both HCV and HEV viral suppression. Conclusion: In conclusion, although more data are required before firm conclusions could be drawn, the combination of sofosbuvir and ribavirin in not immunosuppressed patients with acute hepatitis E may be able to clear HEV infection.
Autochthonous acute hepatitis E: treatment with sofosbuvir and ribavirin / Biliotti, Elisa; Franchi, Cristiana; Spaziante, Martina; Garbuglia, Anna Rosa; Volpicelli, Lorenzo; Palazzo, Donatella; De Angelis, Maurizio; Esvan, Rozenn; Taliani, Gloria. - In: INFECTION. - ISSN 0300-8126. - 46:5(2018), pp. 725-727. [10.1007/s15010-018-1168-7]
Autochthonous acute hepatitis E: treatment with sofosbuvir and ribavirin
Biliotti, Elisa;Spaziante, Martina;Volpicelli, Lorenzo;Esvan, Rozenn;Taliani, Gloria
2018
Abstract
Introduction: Hepatitis E virus (HEV) is an emerging cause of autochthonous-acute-hepatitis and acute-on-chronic-liver-failure in western countries. Treatment is not routinely used, despite ribavirin has a good antiviral effect. In vitro sofosbuvir inhibits HEV replication, but clinical data are lacking. Case report: We report a case of acute-on-chronic-liver-failure due to HEV treated with sofosbuvir and ribavirin. The treatment was capable of rapidly inducing both HCV and HEV viral suppression. Conclusion: In conclusion, although more data are required before firm conclusions could be drawn, the combination of sofosbuvir and ribavirin in not immunosuppressed patients with acute hepatitis E may be able to clear HEV infection.File | Dimensione | Formato | |
---|---|---|---|
Biliotti_Autochthonous-acute-hepatitis_2018.pdf
accesso aperto
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
655.62 kB
Formato
Adobe PDF
|
655.62 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.